<DOC>
	<DOCNO>NCT01573806</DOCNO>
	<brief_summary>Pharmacology Exenatide Pediatric Sepsis , PEPS phase 1-2 research study examine drug safety , drug metabolism , drug action preliminary drug clinical effect four exenatide inject every 12 hour child shock infection ( septic shock ) . The investigator hypothesize exenatide safely dosed child sepsis achieve blood level drug similar achieve teenager type 2 diabetes . The investigator hypothesize injection exenatide child septic shock normalize blood glucose level decrease level inflammation protein blood early course sepsis .</brief_summary>
	<brief_title>Pharmacology Exenatide Pediatric Sepsis</brief_title>
	<detailed_description>Pharmacology Exenatide Pediatric Sepsis , PEPS phase 1-2 investigation examine safety , pharmacokinetics , pharmacodynamics , preliminary clinical efficacy 4 subcutaneous dos exenatide administer every 12 hour child newly diagnose septic shock . The investigator ' long term goal explore potential benefit exenatide : early immunomodulation glucose homeostasis , organ dysfunction , clinically meaningful outcomes associate pediatric sepsis . The current study objective conduct `` 3+3 '' dose escalation study , examine `` best exenatide allometric dose '' generate safety , pharmacokinetic , pharmacodynamic , initial efficacy data large cohort . In Phase 1 ( three allometric dos ; three age stratum ) investigator identify exenatide dose regimen mimic area exenatide concentration curve exenatide dose among adolescent type 2 diabetes minimal adverse event . A total 18 subject expect enrolled Phase 1 . In Phase 2 investigator utilize `` best exenatide allometric dose '' clarify exenatide safety ( adverse event occurence : e.g . nausea , abdominal pain , delay gastric empty , hypoglycemia , pancreatitis , renal dysfunction ) , pharmacokinetics , pharmacodynamics ( glucose homeostasis ; inflammatory cytokine serum concentration ) , effect clinical outcome ( AUC Saturation Index , AUC Vasoactive-Inotropic Score , AUC RIFLE Criteria , Pediatric Logistic Organ Dysfunction Score ; change health-related quality life functional status ) . In Phase 2 , 30 subject age strata ratio 4:1 , exenatide : vehicle , expect enrol .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Age 44 week estimate gestational age 18 year AND Admitted PICU sepsis event AND Vascular catheter capable provide serial blood sample place AND Diagnosis septic shock = sepsis cardiovascular organ dysfunction AND Parents speak English Spanish Greater 12 hour admission PICU enrollment OR Chronic acute dialytic therapy , history renal impairment renal transplantation OR History pancreatitis OR History hypersensitivity Byetta OR History severe gastrointestinal disease gastroparesis OR History diabetes mellitus , type I type II OR History insulin , sulfonyl urea drug , coumarin use OR History hypoglycemia OR History active pregnancy ( effect exenatide fetus unknown ) OR Inability collect serial blood sample OR Previously enrol PEPS study OR Lack commitment aggressive sepsis therapy OR Expectation succumb sepsis event OR Patient foster child and/or ward state OR Sepsis event associate PICUacquired nosocomial infection OR Patient enrol another interventional investigation might obscure potential effect exenatide dose .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>sepsis</keyword>
	<keyword>septic shock</keyword>
	<keyword>child</keyword>
	<keyword>incretins</keyword>
	<keyword>exenatide</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>glucose homeostasis</keyword>
	<keyword>inflammation</keyword>
	<keyword>cytokine</keyword>
	<keyword>health-related quality life</keyword>
	<keyword>functional status</keyword>
</DOC>